MARKET

FDMT

FDMT

4D Molecular Therapeutics Inc.
NASDAQ
15.88
+0.64
+4.20%
Closed 19:30 09/22 EDT
OPEN
15.21
PREV CLOSE
15.24
HIGH
16.23
LOW
15.13
VOLUME
936.97K
TURNOVER
0
52 WEEK HIGH
16.93
52 WEEK LOW
6.47
MARKET CAP
877.28M
P/E (TTM)
-5.7578
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Recursion Pharmaceuticals (RXRX) and Contineum Therapeutics, Inc. Class A (CTNM)
TipRanks · 1d ago
Weekly Report: what happened at FDMT last week (0914-0918)?
Weekly Report · 2d ago
4D Molecular management to meet with B. Riley
TipRanks · 5d ago
This Coinbase Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
Benzinga · 09/14 12:31
4D Molecular Therapeutics Raised to Overweight From Neutral by Cantor Fitzgerald
Dow Jones · 09/14 11:12
4D Molecular Therapeutics Price Target Announced at $20.00/Share by Cantor Fitzgerald
Dow Jones · 09/14 11:12
Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight, Announces $20 Price Target
Benzinga · 09/14 11:03
4D Molecular upgraded to Overweight from Neutral at Cantor Fitzgerald
TipRanks · 09/14 10:40
More
About FDMT
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.

Webull offers 4D Molecular Therapeutics Inc stock information, including NASDAQ: FDMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FDMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FDMT stock methods without spending real money on the virtual paper trading platform.